Bone Marrow Transplantation
Historical
Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy.
Thomas ED, Lochte HL Jr, Lu WC, Ferrebee J.W.
N Engl J Med. 1957;257:491-496.
Description: A first report of a (transiently) successful graft in humans.
PubMed citation number: 13464965
Supralethal whole body irradiation and isologous marrow transplantation in man.
Thomas ED, Lochte HL Jr, Cannon JH, Sahler OD, Ferrebee JW.
J Clin Invest. 1959;38:1709-1716.
Description: The first report of a syngeneic bone marrow transplantation for pediatric ALL. It showed successful engraftment but early relapse: discussion includes speculation about the potential need for a graft versus leukemia effect.
PubMed citation number: 13837954
GVHD and GVL
Antileukemic effect of graft-versus host disease in human recipients of allogeneic-marrow grafts.
Weiden PL, Flournoy N, Thomas ED, et al.
N Engl J Med. 1979;300:1068-1073.
Description: The paper that showed that allogeneic transplantation has a lower relapse rate than syngeneic transplantation, and that patients who have GVHD have a lower risk of relapse, although there was no improvement in survival for those patients with GVHD. Contrary to current thinking, the antileukemic effect appeared stronger against ALL than myeloid malignancies.
PubMed citation number: 34792
Antileukemic effect of chronic graft versus-host disease: contribution to improved survival after allogeneic marrow transplantation.
Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED.
N Engl J Med. 1981;304:1529-1533.
Description: Chronic GVHD also confers antileukemic activity.
PubMed citation number: 7015133
Graft-versus-leukemia reactions after bone marrow transplantation.
Horowitz MM, Gale RP, Sondel PM, et al.
Blood. 1990;75:555-562.
Description: A large retrospective study (2,254 patients) of recipients of HLA-identical sibling transplants (allogeneic and syngeneic) for AML, ALL, and CML, comparing relapse in patients receiving T-cell–depleted marrow or non-TCD marrow, and comparing relapse in patients with or without GVHD. The data support: 1) an antileukemic effect of GVHD 2) an antileukemic effect of allografts independent of GVHD.
PubMed citation number: 2297567
Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH.
N Engl J Med. 1994;330:100-106.
Description: An early paper establishing the antileukemic activity of DLI in relapsed chronic-phase CML after transplantation.
PubMed citation number: 8259165
Prevention of graft versus host disease by inactivation of host antigen-presenting cells.
Shlomchik WD, Couzens MS, Tang CB, et al.
Science. 1999;285:412-415.
Description: In a mouse model of allogeneic BMT, only host antigen-presenting cells are required for initiation of GVHD.
PubMed citation number: 10411505
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.
Miklos DB, Kim HT, Miller KH, et al.
Blood. 2005;105:2973-2978.
Description: A retrospective study looking at plasma antibody responses to minor histocompatibility antigens encoded by the Y chromosome and clinical correlations. The investigators found that male recipients of female grafts are more likely than male recipients of male grafts to develop anti–H-Y antibodies, and the antibodies correlated significantly with the risk of chronic (but not acute) graft-versus-host disease (OR=56.5 by multivariate analysis). Notably, in the samples tested, no patients who developed anti–H-Y antibodies had disease relapse. These are interesting new data implicating B cells in the process of chronic graft-versus-host disease and antitumor immunity.
PubMed citation number: 15613541
Solid Tumors and BMT
Solid cancers after bone marrow transplantation.
Curtis RE, Rowlings PA, Deeg HJ, et al.
N Engl J Med. 1997;336:897-904.
Description: A study of 19,229 allogeneic/syngeneic transplantation patients showing an increased risk of development of solid tumors.
PubMed citation number: 9070469
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
Stadtmauer EA, O’Neill A, Goldstein LJ, et al.
N Engl J Med. 2000;342:1069-1076.
Description: The study that showed no survival benefit for high-dose therapy and autoBMT over conventional chemotherapy in metastatic breast cancer.
PubMed citation number: 10760307
Nonmyeloablative Transplantation
Transplant-lite: induction of graft-versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Khouri IF, Keating M, Korbling M, et al.
J Clin Oncol. 19989;16:2817-2824.
Description: An early description of nonmyeloablative transplantation for CLL/lymphoma.
PubMed citation number: 9704734
Umbilical Cord Blood Transplantation
Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients.
Kurtzberg J, Laughlin M, Graham ML, et al.
N Engl J Med. 1996;335:157-166.
Description: A very early phase 1 study of patients (primarily children) demonstrating the feasibility and safety of unrelated umbilical cord blood transplantation for malignant as well as inherited diseases.
PubMed citation number: 8657213
Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.
Rocha V, Labopin M, Sanz G, et al.
N Engl J Med. 2004;351:2276-2285.
PubMed citation number: 15564544
Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.
Laughlin MJ, Eapen M, Rubinstein P, et al.
N Engl J Med. 2004;351:2265-2275.
PubMed citation number: 15564543
Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies.
Takahashi S, Iseki T, Ooi J, et al.
Blood. 2004;104:3813-3820.
PubMed citation number: 15280199
Description: These 3 publications represent the most current data comparing cord blood grafts to matched unrelated donor grafts in adults with hematologic malignancies. The latter is a single-institution experience in Japan, while the others are retrospective studies using the Eurocord and IBMTR registry data, and the results of the 3 studies have some notable differences. All confirm that cord blood is a reasonable alternative stem cell source if a matched unrelated donor is unavailable; all found that engraftment of cord blood is delayed. The Japanese study found improved transplantation-related mortality and disease-free survival in the cohort receiving cord blood grafts, while the other 2 studies did not. Whether these differences are related to patient selection or differences in genetic heterogeneity (or some other factor) is not entirely clear.
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy.
Barker JN, Weisdorf DJ, DeFor TE, et al.
Blood. 2005;105:1343-1347.
Description: A major limitation of cord blood transplantation in adults is absolute numbers of cells; using 2 partially matched units is shown here to be safe, with encouraging data on time to engraftment. By day 100, 1 cord blood unit predominated in all 23 patients. CD3 + cell number was the variable that correlated with which unit engrafted.
PubMed citation number: 15466923
Review
Cytokine dysregulation and acute graft versus-host disease.
Antin JH, Ferrara JL.
Blood. 1992;80:2964-2968.
PubMed citation number: 1467511
Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect.
Champlin R, Khouri I, Komblau S, Molidrem J, Giralt S.
Oncology (Huntingt). 1999;13:621-628.
PubMed citation number: 10356683
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
Ho VT, Soiffer RJ.
Blood. 2001;98:3192-3204.
PubMed citation number: 11719354
Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?
Korbling M, Anderlini P.
Blood. 2001;98:2900-2908.
PubMed citation number: 11698269
How I treat chronic graft-versus-host disease.
Vogelsang GB.
Blood. 2001;97:1196-1201.
PubMed citation number: 11222360